GP41 Informations sur la molécule
Molecule Name
Transmembrane glycoprotein gp41
Alias de la molécule
HIV-1 (HXB2) GP41,GP41
Drug Development Progress
Nombre de médicaments cliniques11
Nombre de médicaments commercialisés2
Phase de R&D la plus avancéeApproved
Alias de la cible
Submitted name: Transmembrane glycoprotein gp41，env，HIV Envelope Protein gp41，Env polyprotein
Demande de produit
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Sifuvirtide | FS-0101; SFT | Phase 2 Clinical | Tianjin Fusogen Pharmaceuticals Inc | Acquired Immunodeficiency Syndrome; HIV Infections | Details |
| LP-51 | LP-51 | Phase 2 Clinical | Institute Of Pathogenic Biology Chinese Academy Of Medical Sciences | HIV Infections; Sjogren's Syndrome | Details |
| LP-98 | LP-98 | Phase 2 Clinical | Shanxi Kangbao Biological Product Co Ltd | HIV Infections | Details |
| PGT-121 | PGT-121 | Phase 2 Clinical | International Aids Vaccine Initiative, Theraclone Sciences Inc, The Scripps Research Institute Inc, The Ragon Institute Of Mgh, Mit And Harvard | HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral | Details |
| MPER-656 liposome vaccine | MPER-656 | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| Microbicide monoclonal antibody triple combination (Polymun Scientific Immunobiologische Forschung) | Phase 1 Clinical | Polymun Scientific Gmbh | HIV Infections | Details | |
| Elipovimab | GS-9722 | Phase 1 Clinical | Gilead Inc | HIV Infections | Details |
| CPT-31 | CPT-31; CPT31-LA | Phase 1 Clinical | Navigen | Purpura, Thrombocytopenic, Idiopathic; HIV Infections | Details |
| Microbicide Monoclonal Antibody Triple Combination (Polymun) | Phase 1 Clinical | HIV Infections | Details | ||
| HIV vaccine (influenza virus carrier) (Polymun/Lionex) | Phase 1 Clinical | HIV Infections | Details | ||
| FB-1002(Frontier Biotechnologies) | FB-1002(前沿生物) | Phase 1 Clinical | Frontier Biotechnologies Inc, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Coronavirus Disease 2019 (COVID-19) | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Albuvirtide | FB-006M | Approved | Frontier Biotechnologies Inc | 艾可宁 | Mainland China | HIV Infections | Frontier Biotechnologies Inc | 2018-05-23 | Acquired Immunodeficiency Syndrome; HIV Infections | Details |
| Enfuvirtide | T-20; R-698; DP-178 | Approved | F. Hoffmann-La Roche Ltd | Fuzeon | United States | HIV Infections | F. Hoffmann-La Roche Ltd | 2003-03-13 | HIV Infections; Acquired Immunodeficiency Syndrome | Details |